64x Bio
ActiveEnabling next generation medicines. A comprehensive platform and…
This company has previously operated under “64-X”, “64-x”. A rename frequently marks a pivot in positioning or product — useful raw material for variant ideas.
About
The future of medicine is taking shape, but scaling it remains a challenge. Some of the biggest breakthroughs in next generation therapies are being held back by manufacturing constraints. The science is moving fast, but the infrastructure is still catching up. Our VectorSelect platform is designed to unlock the scale these therapies need to survive. We combine massively parallelized screens with computational insights to engineer high yield cell lines and production technologies — accelerating the manufacturing of advanced therapies from the inside out.
Founders · 1
Lexi Rovner, PhD is the CEO & co-founder of 64x Bio, a spinout of Harvard Medical School and the Wyss Institute. Lexi completed her PhD at Yale University and her postdoctoral work in George Church’s lab at Harvard Medical School, where she co-founded the company alongside George, Pam Silver, Jeff Way, and David Thompson. Lexi is a Y Combinator alum, a 2022 Endpoints 20 under 40 Next-Generation Biotech Leader, and a 2022 Bloomberg New Economy Catalyst Awardee.
Related startups
Democratizing gene therapy by reinventing its manufacturing and…
We grow cells for biotech companies.
